Arrowhead Pharma (ARWR)

$22.03 -0.31 (-1.39%)
Market Cap 3.01B
Revenue (ttm) 3.55M
Net Income (ttm) -599.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,887.04%
Debt to Equity Ratio 0.46
Volume 2,388,600
Avg Vol 2,117,120
Day's Range N/A - N/A
Shares Out 138.26M
Stochastic %K 99%
Beta 0.94
Analysts Strong Sell
Price Target $43.71

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
Pantherfan7979
Pantherfan7979 Aug. 28 at 3:58 PM
$ARWR Not to late to jump in the ARWR pool to all you on the fence. Lots of upside for this criminally undervalued stock
3 · Reply
johnnygogogo
johnnygogogo Aug. 28 at 3:12 PM
$ARWR does this mean I need to start writing it as “Stanley?” @skeezbag “Morgan Stanley 23rd Annual Global Healthcare Conference – September 8-10, 2025 Type: Fireside Chat Presentation Date/Time: September 10, 2025, 11:30 a.m. EDT”
0 · Reply
Jschwarma
Jschwarma Aug. 28 at 3:11 PM
$ARWR september options are flying
0 · Reply
aliliimr
aliliimr Aug. 28 at 2:33 PM
$ARWR average of 13.8 looking nice 🙂 waiting for … “i dont know whats the right price to sell at” 😀
3 · Reply
skeezbag
skeezbag Aug. 28 at 2:02 PM
$ARWR RAGE SHEEP! BAAAAAAAAAA 🐑🐑🐑🐑🐑
0 · Reply
TheSteveSmiths1
TheSteveSmiths1 Aug. 28 at 1:17 AM
$ARWR Im hoping for a bunch of good news for the rest of the year. If ARWR gets a multi-billion dollar ARO-RAGE partnership along with the Nov PDUFA, I'm thinking $50+ by December.
0 · Reply
HokieStock
HokieStock Aug. 28 at 12:36 AM
$ARWR The deal with Sanofi closed on the 25th. Visirna has already removed it from the product portfolio. Interesting though CFB shows worldwide rights. Ang and HSD show China. Moving parts happening. So positive ARWR should be cash flow positive or more neutral this coming quarter.
0 · Reply
newarray
newarray Aug. 27 at 7:49 PM
$ARWR 40+ in a month?
0 · Reply
johnnygogogo
johnnygogogo Aug. 27 at 7:45 PM
$ARWR chart technicians right now cc: @skeezbag
0 · Reply
Steppinstone
Steppinstone Aug. 27 at 7:28 PM
$ARWR There are only two established RNAi platform companies in the stock market today in my opinion, ALNY and ARWR. Finally, it may be time for ARWR to close the gap a bit in terms of MC. Plozasiran may be the drug to do it for ARWR. It works wonders on trigs at a low 25 mg dose. The upcoming poster presentation should be impressive.
2 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 2 days ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 16 days ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 20 days ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 22 days ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 4 weeks ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2025, 4:30 PM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Jul 22, 2025, 1:30 PM EDT - 5 weeks ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 21, 2025, 4:01 PM EDT - 5 weeks ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 23, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 3 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Jun 2, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 9:56 PM EDT - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025, 4:01 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 7, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 30, 2025, 4:01 PM EDT - 4 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 15, 2025, 4:00 PM EDT - 4 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21, 2025, 5:56 PM EDT - 5 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 10, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Mar 6, 2025, 8:45 AM EST - 6 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 28, 2025, 9:00 AM EST - 6 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 25, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 11:53 AM EST - 6 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 6 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 6 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 9:35 PM EST - 7 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 4:01 PM EST - 7 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Feb 10, 2025, 8:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Jan 22, 2025, 5:54 PM EST - 7 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

GWRE

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 22, 2025, 4:00 PM EST - 7 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Jan 17, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 23, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 11, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 3, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Dec 2, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 11:08 PM EST - 9 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Nov 26, 2024, 4:00 PM EST - 9 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Nov 26, 2024, 7:00 AM EST - 9 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

SRPT

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Nov 18, 2024, 7:31 AM EST - 10 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Nov 18, 2024, 7:30 AM EST - 10 months ago

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Nov 5, 2024, 7:30 AM EST - 10 months ago

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Nov 4, 2024, 7:30 AM EST - 10 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Nov 1, 2024, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Sep 23, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Sep 3, 2024, 11:01 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Sep 2, 2024, 6:36 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Pantherfan7979
Pantherfan7979 Aug. 28 at 3:58 PM
$ARWR Not to late to jump in the ARWR pool to all you on the fence. Lots of upside for this criminally undervalued stock
3 · Reply
johnnygogogo
johnnygogogo Aug. 28 at 3:12 PM
$ARWR does this mean I need to start writing it as “Stanley?” @skeezbag “Morgan Stanley 23rd Annual Global Healthcare Conference – September 8-10, 2025 Type: Fireside Chat Presentation Date/Time: September 10, 2025, 11:30 a.m. EDT”
0 · Reply
Jschwarma
Jschwarma Aug. 28 at 3:11 PM
$ARWR september options are flying
0 · Reply
aliliimr
aliliimr Aug. 28 at 2:33 PM
$ARWR average of 13.8 looking nice 🙂 waiting for … “i dont know whats the right price to sell at” 😀
3 · Reply
skeezbag
skeezbag Aug. 28 at 2:02 PM
$ARWR RAGE SHEEP! BAAAAAAAAAA 🐑🐑🐑🐑🐑
0 · Reply
TheSteveSmiths1
TheSteveSmiths1 Aug. 28 at 1:17 AM
$ARWR Im hoping for a bunch of good news for the rest of the year. If ARWR gets a multi-billion dollar ARO-RAGE partnership along with the Nov PDUFA, I'm thinking $50+ by December.
0 · Reply
HokieStock
HokieStock Aug. 28 at 12:36 AM
$ARWR The deal with Sanofi closed on the 25th. Visirna has already removed it from the product portfolio. Interesting though CFB shows worldwide rights. Ang and HSD show China. Moving parts happening. So positive ARWR should be cash flow positive or more neutral this coming quarter.
0 · Reply
newarray
newarray Aug. 27 at 7:49 PM
$ARWR 40+ in a month?
0 · Reply
johnnygogogo
johnnygogogo Aug. 27 at 7:45 PM
$ARWR chart technicians right now cc: @skeezbag
0 · Reply
Steppinstone
Steppinstone Aug. 27 at 7:28 PM
$ARWR There are only two established RNAi platform companies in the stock market today in my opinion, ALNY and ARWR. Finally, it may be time for ARWR to close the gap a bit in terms of MC. Plozasiran may be the drug to do it for ARWR. It works wonders on trigs at a low 25 mg dose. The upcoming poster presentation should be impressive.
2 · Reply
johnnygogogo
johnnygogogo Aug. 27 at 7:06 PM
$ARWR this but change the lyric to “Mani”: https://m.youtube.com/watch?v=9P202C3mm8g
0 · Reply
skeezbag
skeezbag Aug. 27 at 4:31 PM
$ARWR apparently nvda approval is required first
1 · Reply
Mattie2
Mattie2 Aug. 27 at 1:55 PM
$ARWR Goooo turd
0 · Reply
skeezbag
skeezbag Aug. 27 at 1:38 PM
$ARWR So is Citigroup going to ask what plozasiran treats or do they now know that since their stupid question at the last quarterly call RAGE BITCHES
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Aug. 26 at 10:38 PM
$ARWR looking forward to $50+ post pdufa
1 · Reply
Steppinstone
Steppinstone Aug. 25 at 6:06 PM
$ARWR IMO, ARWR may get a bounce when IONS releases its SHTG data in Sept. The SHTG patient population in the US is probably bigger than both of these sized biotech pharma companies can handle. These APOC inhibitors are super valuable. Wouldn’t be surprised if either one of the companies gets acquired after FDA approval for SHTG. ARWR’s plozasiran is best in class though.
0 · Reply
Jschwarma
Jschwarma Aug. 25 at 1:54 PM
$ARWR 3500 Sept 24s traded at $.80 3500 Sept 17s traded at $4.60 something is coming
2 · Reply
W15E
W15E Aug. 24 at 11:10 PM
$ARWR hmm 🧐
0 · Reply
TapeStrike
TapeStrike Aug. 23 at 6:02 AM
$ARWR Arrowhead Pharmaceuticals is a RNAi therapeutics company with clinical stage pipeline and partnerships
0 · Reply
RokuInvestor
RokuInvestor Aug. 22 at 11:04 PM
$ARWR if you just bought $ALNY you would be up so much.
0 · Reply
skeezbag
skeezbag Aug. 22 at 7:55 PM
$ARWR oh hi fake vwap
1 · Reply
FreeManTrading
FreeManTrading Aug. 22 at 6:39 PM
$SRPT $ARWR seems like we traded prices with them ever since they sold their shares 😭
0 · Reply